After 6 months of nusinersen treatment, IL-31 expression in CSF of SMA patients with two copies of SMN2 was higher compared to patients carrying three copies (p = 0.011) and four copies (p = 0.016). Here, SMN2 is linked to proximal spinal muscular atrophy.